Research

The research activities of the Section of Hematology include both clinical and laboratory research. Details of research interests of each faculty are noted in their individual pages.

Current areas of laboratory research programs include immunobiology of plasma cell diseases, and cellular and molecular biology of blood cell production and hematopoiesis. The research activities are funded by the National Institutes of Health.

Areas of clinical research interest include myeloma and related plasma cell disorders, coagulopathies and non-malignant hematology , sickle cell disease, and palliative care .Other faculty affiliated with the section also carry out basic and clinical research related to hematology. Research programs in hematologic malignancies are in close collaboration with colleagues in the Hematology Program at Yale Cancer Center.

In addition to the individual research programs of primary faculty members of the Section of Hematology, collaborative research projects are ongoing with faculty members of several other departments, such as Laboratory Medicine, Pathology, Immunobiology and Genetics, who have common research interests

Publications

2024

Ezrin drives adaptation of monocytes to the inflamed lung microenvironmentGudneppanavar R, Di Pietro C, H Öz H, Zhang P, Cheng E, Huang P, Tebaldi T, Biancon G, Halene S, Hoppe A, Kim C, Gonzalez A, Krause D, Egan M, Gupta N, Murray T, Bruscia E. Ezrin drives adaptation of monocytes to the inflamed lung microenvironment. Cell Death & Disease 2024, 15: 864. PMID: 39613751, PMCID: PMC11607083, DOI: 10.1038/s41419-024-07255-8.
Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemiaMims A, Xie Z, Potluri R, Rotter D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39606887, DOI: 10.1080/10428194.2024.2425792.
Comparative proteomic analysis of human vitreous in rhegmatogenous retinal detachment and diabetic retinopathy reveals a common pathway and potential therapeutic targetBrighenti T, Neri G, Mazzola M, Tomé G, Scalfati M, Peroni D, Belli R, Zampedri E, Tebaldi T, Borello U, Romanelli F, Casarosa S. Comparative proteomic analysis of human vitreous in rhegmatogenous retinal detachment and diabetic retinopathy reveals a common pathway and potential therapeutic target. Clinical Proteomics 2024, 21: 63. PMID: 39609746, PMCID: PMC11603643, DOI: 10.1186/s12014-024-09515-3.
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation studyIyer S, Sica R, Ho P, Prica A, Zain J, Foss F, Hu B, Beitinjaneh A, Weng W, Kim Y, Khodadoust M, Huen A, Williams L, Ma A, Huang E, Ganpule A, Nagar S, Sripakdeevong P, Cullingford E, Karnik S, Dequeant M, Patel J, He X, Li Z, He Q, Mendonez J, Keegan A, Horwitz S. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. The Lancet Oncology 2024 PMID: 39617017, DOI: 10.1016/s1470-2045(24)00508-4.
Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohortJaber Chehayeb R, Singh J, Matute-Martinez C, Chen N, Guajardo A, Lin D, Jayakrishnan R, Christofides A, Leveille E, Im Y, Biancon G, VanOudenhove J, Ibrahim E, Ardasheva A, Jha A, Hwa J, Halene S, Kwan J. Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort. Cardio-Oncology 2024, 10: 84. PMID: 39587635, PMCID: PMC11590368, DOI: 10.1186/s40959-024-00289-z.
Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AMLAlhajahjeh A, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Huntington S, Stahl M, Goshua G, Bewersdorf J, Zeidan A. Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39560957, DOI: 10.1080/10428194.2024.2426073.
Abstract A016: YBX1 is a negative regulator of post-transcriptional program associated with invasion and metastasis in cSCCSol S, Mandinova A, Boncimino F, Todorova K, Di Cicco E, Tebaldi T, Bucciarelli G. Abstract A016: YBX1 is a negative regulator of post-transcriptional program associated with invasion and metastasis in cSCC. Molecular Cancer Therapeutics 2024, 23: a016-a016. DOI: 10.1158/1538-8514.rnadrivers24-a016.
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington S, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith S, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson P, Grover N, Merril M, Crombie J, Shafagati N, Sterling C, Nastoupil L, Epperla N, Ayers E. Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers. Haematologica 2024, 0. PMID: 39540227, DOI: 10.3324/haematol.2024.285977.
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge studySekeres M, Santini V, Díez-Campelo M, Komrokji R, Fenaux P, Savona M, Madanat Y, Valcárcel-Ferreiras D, Oliva E, Regnault A, Creel K, Sengupta N, Dougherty S, Shah S, Sun L, Wan Y, Navada S, Zeidan A, Platzbecker U. Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study. Leukemia & Lymphoma 2024, ahead-of-print: 1-6. PMID: 39535901, DOI: 10.1080/10428194.2024.2426057.
Abstract 4144255: Treatment of Human Engineered Heart Tissue with Serum from Cancer Patients with Clonal Hematopoiesis of Indeterminate Potential Cytokine Leads to Impaired FunctionKaur H, Halder S, Espinoza J, Chen N, VanOudenhove J, Biancon G, Gu S, Chakraborty R, Jain K, Park J, Qyang Y, Ibrahim E, Halene S, Hwa J, Campbell S, Jha A, Kwan J. Abstract 4144255: Treatment of Human Engineered Heart Tissue with Serum from Cancer Patients with Clonal Hematopoiesis of Indeterminate Potential Cytokine Leads to Impaired Function. Circulation 2024, 150: a4144255-a4144255. DOI: 10.1161/circ.150.suppl_1.4144255.
GPR68 supports AML cells through the calcium/calcineurin pro-survival pathway and confers chemoresistance by mediating glucose metabolic symbiosisHe X, Hawkins C, Lawley L, Phan T, Park I, Joven N, Zhang J, Wunderlich M, Mizukawa B, Pei S, Patel A, VanOudenhove J, Halene S, Fang J. GPR68 supports AML cells through the calcium/calcineurin pro-survival pathway and confers chemoresistance by mediating glucose metabolic symbiosis. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2024, 1871: 167565. PMID: 39522891, DOI: 10.1016/j.bbadis.2024.167565.
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDSNorman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan A. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Review Of Hematology 2024, 17: 755-767. PMID: 39474840, DOI: 10.1080/17474086.2024.2422554.
In-Human Clinical Experience with Direct Stick Embolization of Low-Flow Vascular Malformations Using an mTOR InhibitorRestrepo-Espinosa V, Lee A, Prozora S, Patel P, Nassiri N. In-Human Clinical Experience with Direct Stick Embolization of Low-Flow Vascular Malformations Using an mTOR Inhibitor. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2024, 101997. PMID: 39515753, DOI: 10.1016/j.jvsv.2024.101997.
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?El Chaer F, Perissinotti A, Loghavi S, Zeidan A. Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time? Leukemia 2024, 1-7. PMID: 39496917, DOI: 10.1038/s41375-024-02458-6.
Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database.Alhajahjeh A, Rotter L, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database. JCO Global Oncology 2024, 10: e2400316. PMID: 39621951, DOI: 10.1200/go-24-00316.
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortiumHan J, Koh M, Boussi L, Sorial M, McCabe S, Peng L, Singh S, Eche-Ugwu I, Gabler J, Fernandez Turizo M, MacVicar C, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Horwitz S, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim J, Cho J, Eipe T, Shet T, Epari S, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al-Mansour M, Ford J, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Iwasaki M, Bhanushali F, O'Connor O, Marchi E, Shen C, Shah D, Jain S. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium. Blood Advances 2024 PMID: 39481087, DOI: 10.1182/bloodadvances.2024014674.
Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival BenefitKume K, Iida M, Iwaya T, Yashima-Abo A, Koizumi Y, Endo A, Wade K, Hiraki H, Calvert V, Wulfkuhle J, Espina V, Siwak D, Lu Y, Takemoto K, Suzuki Y, Sasaki Y, Tokino T, Petricoin E, Liotta L, Mills G, Nishizuka S. Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit. Molecular & Cellular Proteomics 2024, 23: 100870. PMID: 39461475, PMCID: PMC11621936, DOI: 10.1016/j.mcpro.2024.100870.
Future directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biologyDella Porta M, Bewersdorf J, Wang Y, Hasserjian R. Future directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biology. Histopathology 2024 PMID: 39450427, DOI: 10.1111/his.15353.
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantationEpperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, PMCID: PMC11532746, DOI: 10.1182/bloodadvances.2024013743.
Analyzing determinants of premature trial discontinuation in leukemia clinical trialsRotter L, Alhajahjeh A, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Analyzing determinants of premature trial discontinuation in leukemia clinical trials. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39440622, DOI: 10.1080/10428194.2024.2416565.
Systemic Estrogen Therapy and Thrombosis: A Call for Individualized Clinical Decision Making in the Acute Care Setting.Restrepo V, Martin K, Van Doren L. Systemic Estrogen Therapy and Thrombosis: A Call for Individualized Clinical Decision Making in the Acute Care Setting. Clin Ther 2024 PMID: 39443265, DOI: 10.1016/j.clinthera.2024.09.026.
Abstract B008: Rescuing neoantigen-specific CD8+ T-cell immunity from tumor- microenvironment-mediated immunosuppression in pancreatic cancerJacox J, Foster G, Vattem C, Shah D, Sogunro A, Joshi N, Muzumdar M. Abstract B008: Rescuing neoantigen-specific CD8+ T-cell immunity from tumor- microenvironment-mediated immunosuppression in pancreatic cancer. Cancer Immunology Research 2024, 12: b008-b008. DOI: 10.1158/2326-6074.tumimm24-b008.
Incidence of bacterial blood stream infections in patients with acute GVHDWallis W, Gulbis A, Wang T, Lee C, Sharma A, Williams K, Nishihori T, Prestidge T, Gowda L, Byrne M, Krem M, MacMillan M, Kitko C, Pidala J, Spellman S, Lee S, Alousi A. Incidence of bacterial blood stream infections in patients with acute GVHD. Bone Marrow Transplantation 2024, 1-6. PMID: 39420192, DOI: 10.1038/s41409-024-02426-9.
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directionsBidikian A, Bewersdorf J, Shallis R, Getz T, Stempel J, Kewan T, Stahl M, Zeidan A. Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions. Expert Review Of Anticancer Therapy 2024, 24: 1131-1146. PMID: 39367718, DOI: 10.1080/14737140.2024.2414071.
Disentangling gender, sex, and biology: a mixed methods study of gender identity data collection toolsAlpert A, Hernandez T, Ruddick R, Manzano C, Adams S, Rivers L, Ramos-Pibernus A, Sevelius J, Poteat T, Obedin-Maliver J, Cicero E, Radix A, Lett E, Operario D, Chapman B, Wittink M, Cupertino A, Murchison G, Nunez-Smith M, Cartujano-Barrera F. Disentangling gender, sex, and biology: a mixed methods study of gender identity data collection tools. Patient Education And Counseling 2024, 130: 108473. PMID: 39471780, DOI: 10.1016/j.pec.2024.108473.
Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of SurvivalAjufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Buckley S, Derkach A, Roman‐Torres K, Rampal R. Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival. European Journal Of Haematology 2024 PMID: 39400386, DOI: 10.1111/ejh.14321.
High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional seriesEpperla N, Zayac A, Landsburg D, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Bond D, Evens A, Naik S, Kamdar M, Haverkos B, Karmali R, Farooq U, Vose J, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Advances 2024, 8: 5355-5364. PMID: 39189932, PMCID: PMC11568788, DOI: 10.1182/bloodadvances.2024013791.
Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Post-Authorization Safety Surveillance StudyPoloni A, Raaschou-Jensen K, Mohedo F, Paolini S, Oliva E, Buccisano F, Vasconcelos A, Kim I, Makwana A, Bernasconi D, Rosettani B, Prebet T, Santini V. Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Post-Authorization Safety Surveillance Study. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39516085, DOI: 10.1016/j.clml.2024.10.007.
Splicing the Difference: Harnessing the Complexity of the Transcriptome in HematopoiesisMaul-Newby H, Halene S. Splicing the Difference: Harnessing the Complexity of the Transcriptome in Hematopoiesis. Experimental Hematology 2024, 140: 104655. PMID: 39393608, DOI: 10.1016/j.exphem.2024.104655.
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic SyndromesKomrokji R, Lanino L, Ball S, Bewersdorf J, Marchetti M, Maggioni G, Travaglino E, Al Ali N, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain A, Aguirre L, Tinsley-Vance S, Schwabkey Z, Chan O, Xie Z, Brunner A, Kuykendall A, Bennett J, Buckstein R, Bejar R, Carraway H, DeZern A, Griffiths E, Halene S, Hasserjian R, Lancet J, List A, Loghavi S, Odenike O, Padron E, Patnaik M, Roboz G, Stahl M, Sekeres M, Steensma D, Savona M, Taylor J, Xu M, Sweet K, Sallman D, Nimer S, Hourigan C, Wei A, Sauta E, D’Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate U, Sanz G, Efficace F, Gore S, Kim T, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang A, Foucar M, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht A, Ades L, Zeidan A, Della Porta M, Syndromes I. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. The Lancet Haematology 2024, 11: e862-e872. PMID: 39393368, DOI: 10.1016/s2352-3026(24)00251-5.
Cost-effectiveness of iptacopan in paroxysmal nocturnal hemoglobinuriaIto S, Chetlapalli K, Wang D, Potnis K, Richmond R, Krumholz H, Lee A, Cuker A, Goshua G. Cost-effectiveness of iptacopan in paroxysmal nocturnal hemoglobinuria. Blood 2024 PMID: 39374533, DOI: 10.1182/blood.2024025176.
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])Aakash F, Gisriel S, Zeidan A, Bennett J, Bejar R, Bewersdorf J, Borate U, Boultwood J, Brunner A, Buckstein R, Carraway H, Churpek J, Daver N, DeZern A, Efficace F, Fenaux P, Figueroa M, Garcia-Manero G, Gore S, Greenberg P, Griffiths E, Halene S, Hourigan C, Kim T, Kim N, Komrokji R, Kutchroo V, List A, Little R, Majeti R, Nazha A, Nimer S, Odenike O, Padron E, Patnaik M, Platzbecker U, Della Porta M, Roboz G, Sallman D, Santini V, Sanz G, Savona M, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Wei A, Xie Z, Xu M, Hasserjian R, Loghavi S. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Modern Pathology 2024, 37: 100615. PMID: 39322118, DOI: 10.1016/j.modpat.2024.100615.
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.Gyurkocza B, Nath R, Seropian S, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Hari P, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, Van Besien K, Schuster M, Law A, Larkin K, Pandit-Taskar N, Rowley S, Munshi P, Cook R, Levy M, Lazarus H, Sandmaier B, Pagel J, Reddy V, MacDougall J, McNamara K, Spross J, Haeuber E, Vusirikala M, Nahar A, Desai A, Giralt S. Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. Journal Of Clinical Oncology 2024, jco2302018. PMID: 39298738, DOI: 10.1200/jco.23.02018.
Recent Insights of Molecular Approaches to Study Brain Tumor Associated Seizure and EpilepsyDr. Rajesh Kumar Kar,"Recent Insights of Molecular Approaches to Study Brain Tumor Associated Seizure and Epilepsy", Recent Trends in Diabetes and Cancer Research and its Management,IIP Series, Volume 1, September, 2024, Page no.21-47, e-ISBN: 978-1-68576-521-7, DOI/Link: https://www.doi.org/10.58532/nbennurrdch2
Does cancer clinical trial enrollment for sexual and gender minority people differ from heterosexual, cisgender people?Alpert A, Obedin-Maliver J, Gjelsvik A, Amanullah S, Shireman T, Blosnich J. Does cancer clinical trial enrollment for sexual and gender minority people differ from heterosexual, cisgender people? Contemporary Clinical Trials 2024, 146: 107695. PMID: 39303766, DOI: 10.1016/j.cct.2024.107695.
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AMLBewersdorf J, Shimony S, Shallis R, Liu Y, Berton G, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Bystrom R, Lindsley R, Chen E, Perez J, Stein A, Pullarkat V, Aldoss I, DeAngelo D, Neuberg D, Stone R, Garciaz S, Ball B, Stahl M. Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML. Blood Advances 2024, 8: 4845-4855. PMID: 38941537, PMCID: PMC11416634, DOI: 10.1182/bloodadvances.2024012858.
Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studiesGu S, Butt A, Schulz V, Rinder H, Lee A, Gallagher P, Hwa J, Bona R. Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies. Blood Cells Molecules And Diseases 2024, 110: 102893. PMID: 39260211, DOI: 10.1016/j.bcmd.2024.102893.
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A multi‐institutional studyBadar T, Narra R, Mims A, Heckman M, Shallis R, Fahad S, Hunter C, Kota V, Othman T, Jonas B, Desai S, de Camargo Correia G, Patel A, DuVall A, Palmisiano N, Curran E, Omer Z, Advani A, Atallah E, Litzow M. Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A multi‐institutional study. American Journal Of Hematology 2024, 99: 2388-2391. PMID: 39253997, DOI: 10.1002/ajh.27475.
Real World Data on Efficacy and Safety of EPOCH in T-Cell LymphomaStraining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.
Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database StudyBorate U, Seiter K, Potluri R, Mazumder D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study. Advances In Therapy 2024, 41: 4049-4064. PMID: 39240504, PMCID: PMC11480148, DOI: 10.1007/s12325-024-02947-1.
Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapyAchar R, McCormick B, Dworkin E, Geramita E, Im A, Patel A, Badar T, Shallis R. Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy. Leukemia Research 2024, 146: 107577. PMID: 39278123, DOI: 10.1016/j.leukres.2024.107577.
Clinical and Histologic Variants of CD8+ Cutaneous T-Cell LymphomasSwallow M, Micevic G, Zhou A, Carlson K, Foss F, Girardi M. Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas. Cancers 2024, 16: 3087. PMID: 39272944, PMCID: PMC11394026, DOI: 10.3390/cancers16173087.
Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insightsMuradashvili T, Liu Y, VanOudenhove J, Gu S, Krause D, Montanari F, Carlino M, Mancuso R, Stempel J, Halene S, Zeidan A, Podoltsev N, Neparidze N. Aplastic anemia in association with multiple myeloma: clinical and pathophysiological insights. Leukemia & Lymphoma 2024, ahead-of-print: 1-8. PMID: 39225418, DOI: 10.1080/10428194.2024.2393260.
Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma.Leveille E, Kothari S, Cosgun K, Mlynarczyk C, Müschen M. Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma. Cancer Discovery 2024, 14: 1577-1580. PMID: 39228298, DOI: 10.1158/2159-8290.cd-24-0644.
MM-416 Impact of Social Needs and Identity Experiences on the Burden of Illness for Patients with Multiple Myeloma: A Mixed-Methods StudyNeparidze N, Godara A, Godara D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. MM-416 Impact of Social Needs and Identity Experiences on the Burden of Illness for Patients with Multiple Myeloma: A Mixed-Methods Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s555-s556. DOI: 10.1016/s2152-2650(24)01678-1.
Impact of Social Needs and Identity Experiences on the Burden of Illness for Patients with Multiple Myeloma: A Mixed-Methods StudyNeparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Impact of Social Needs and Identity Experiences on the Burden of Illness for Patients with Multiple Myeloma: A Mixed-Methods Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s238. DOI: 10.1016/s2152-2650(24)00965-0.
Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs . BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA)Huntington S, Jawaid D, Marx S, Puckett J, Manzoor B, Li S, Emechebe N, Kamal-Bahl S, Ravelo A, Budlong H, Doshi J. Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs . BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s180. DOI: 10.1016/s2152-2650(24)00571-8.
Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase InhibitorsRavelo A, Patel A, To T, Li S, Huntington S. Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s180. DOI: 10.1016/s2152-2650(24)00569-x.
CLL-171 Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs. BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA)Huntington S, Jawaid D, Marx S, Puckett J, Manzoor B, Li S, Emechebe N, Sachin-Bahl S, Ravelo A, Budlong H, Doshi J. CLL-171 Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs. BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s345-s346. DOI: 10.1016/s2152-2650(24)01265-5.
CLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase InhibitorsRavelo A, Patel A, To T, Li S, Huntington S. CLL-144 Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s345. DOI: 10.1016/s2152-2650(24)01263-1.
Long-Term Follow-Up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA TrialSeropian S, Gyurkocza B, Nath R, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, Van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Vusirikala M, Sandmaier B, Pagel J, Desai A, Giralt S. Long-Term Follow-Up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s173. DOI: 10.1016/s2152-2650(24)00518-4.
AML-545 Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA TrialSeropian S, Gyurkocza B, Nath R, Choe H, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, Van Besien K, Schuster M, Law A, Mayer S, Lazarus H, Spross J, Li K, Vusirikala M, Sandmaier B, Pagel J, Desai A, Giralt S. AML-545 Long-Term Follow-up Demonstrates Ongoing Efficacy Benefit of 131I-Apamistamab-led Allogeneic Hematopoietic Cell Transplantation in Older Patients With Active, R/R AML in the Phase 3 SIERRA Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s319. DOI: 10.1016/s2152-2650(24)01210-2.
Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 TrialMaruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Narita T, Foss F, Yamauchi N, Yuda J, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Inoue A, Tachibana M, Hizukuri Y, Horwitz S, Jacobsen E. Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s229. DOI: 10.1016/s2152-2650(24)00908-x.
TCL-391 Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 TrialMaruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Narita T, Foss F, Yamauchi N, Yuda J, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Maruyama A, Tachibana M, Hizukuri Y, Horwitz S, Jacobsen E. TCL-391 Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s523-s524. DOI: 10.1016/s2152-2650(24)01617-3.
ABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL StudyDahiya S, Hirayama A, Schuster S, Ortega J, Morschhauser F, Garcia-Sancho A, Kuruvilla J, Izutsu K, Barbui A, Borchmann P, Mielke S, Cartron G, Ghesquieres H, Goto H, Varadarajan I, Kamdar M, Isufi I, Farazi T, Kao G, Vedal M, Bhatnagar R, Nishii R, Papuga J, Palomba M. ABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s462-s463. DOI: 10.1016/s2152-2650(24)01497-6.
Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL StudyDahiya S, Hirayama A, Schuster S, Ortega J, Morschhauser F, Garcia-Sancho A, Kuruvilla J, Izutsu K, Barbui A, Borchmann P, Mielke S, Cartron G, Ghesquieres H, Goto H, Varadarajan I, Kamdar M, Isufi I, Farazi T, Kao G, Vedal M, Bhatnagar R, Nishii R, Papuga J, Palomba M. Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s212. DOI: 10.1016/s2152-2650(24)00792-4.
MDS-156 Efficacy of Imetelstat on Red Blood Cell (RBC)-Transfusion Independence (TI) in the Absence of Platelet Transfusions or Myeloid Growth Factors (MGF) in IMergeZeidan A, Santini V, Platzbecker U, Sekeres M, Savona M, Fenaux P, Madanat Y, Raza A, Xia Q, Sun L, Riggs J, Shah S, Navada S, Berry T, Komrokji R. MDS-156 Efficacy of Imetelstat on Red Blood Cell (RBC)-Transfusion Independence (TI) in the Absence of Platelet Transfusions or Myeloid Growth Factors (MGF) in IMerge. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s386. DOI: 10.1016/s2152-2650(24)01344-2.
Efficacy of Imetelstat on Red Blood Cell (RBC)-Transfusion Independence (TI) in the Absence of Platelet Transfusions or Myeloid Growth Factors (MGF) in IMergeZeidan A, Santini V, Platzbecker U, Sekeres M, Savona M, Fenaux P, Madanat Y, Raza A, Xia Q, Sun L, Riggs J, Shah S, Navada S, Berry T, Komrokji R. Efficacy of Imetelstat on Red Blood Cell (RBC)-Transfusion Independence (TI) in the Absence of Platelet Transfusions or Myeloid Growth Factors (MGF) in IMerge. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s191. DOI: 10.1016/s2152-2650(24)00646-3.
MDS-167 Multilineage and Safety Results From the COMMANDS Trial in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS)Garcia-Manero G, Della Porta M, Santini V, Zeidan A, Komrokji R, Li J, Pilot R, Kreitz S, Pozharskaya V, Keeperman K, Lai Y, Valcarcel D, Fenaux P, Platzbecker U. MDS-167 Multilineage and Safety Results From the COMMANDS Trial in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s388. DOI: 10.1016/s2152-2650(24)01347-8.
MDS-772 Time Toxicity for Patients Receiving Oral Versus Parenteral Hypomethylating Agents for Myelodysplastic Syndromes/NeoplasmsZeidan A, Olopoenia A, Costantino H, Modi K, Salimi T, Washington T, Krenitsky J, Epstein R. MDS-772 Time Toxicity for Patients Receiving Oral Versus Parenteral Hypomethylating Agents for Myelodysplastic Syndromes/Neoplasms. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s406. DOI: 10.1016/s2152-2650(24)01382-x.
MDS-166 Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS TrialZeidan A, Platzbecker U, Della Porta M, Santini V, Garcia-Manero G, Li J, Kreitz S, Pozharskaya V, Rose S, Lai Y, Davidárcel D, Fenaux P, Shortt J, Komrokji R. MDS-166 Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s387-s388. DOI: 10.1016/s2152-2650(24)01346-6.
Time Toxicity for Patients Receiving Oral Versus Parenteral Hypomethylating Agents for Myelodysplastic Syndromes/NeoplasmsZeidan A, Olopoenia A, Costantino H, Modi K, Salimi T, Washington T, Krenitsky J, Epstein R. Time Toxicity for Patients Receiving Oral Versus Parenteral Hypomethylating Agents for Myelodysplastic Syndromes/Neoplasms. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s197. DOI: 10.1016/s2152-2650(24)00684-0.
MDS-157 Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)Santini V, Komrokji R, Sekeres M, Savona M, Fenaux P, Madanat Y, Oliva E, Buckstein R, Annaášová A, Germing U, Mittelman M, Thepot S, Riggs J, Dougherty S, Berry T, Navada S, Xia Q, Sun L, Zeidan A, Platzbecker U. MDS-157 Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s386-s387. DOI: 10.1016/s2152-2650(24)01345-4.
Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)Santini V, Komrokji R, Sekeres M, Savona M, Fenaux P, Madanat Y, Oliva E, Buckstein R, Jonášová A, Germing U, Mittelman M, Thepot S, Riggs J, Dougherty S, Berry T, Navada S, Xia Q, Sun L, Zeidan A, Platzbecker U. Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s192. DOI: 10.1016/s2152-2650(24)00647-5.
Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)Santini V, Komrokji R, Sekeres M, Savona M, Fenaux P, Madanat Y, Oliva E, Buckstein R, Jonášová A, Germing U, Mittelman M, Thepot S, Riggs J, Dougherty S, Berry T, Navada S, Xia Q, Sun L, Zeidan A, Platzbecker U. Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s153. DOI: 10.1016/s2152-2650(24)00388-4.
Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS TrialZeidan A, Platzbecker U, Della Porta M, Santini V, Garcia-Manero G, Li J, Kreitz S, Pozharskaya V, Rose S, Lai Y, Valcárcel D, Fenaux P, Shortt J, Komrokji R. Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s192. DOI: 10.1016/s2152-2650(24)00648-7.
Multilineage and Safety Results From the COMMANDS Trial in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS)Garcia-Manero G, Della Porta M, Santini V, Zeidan A, Komrokji R, Li J, Pilot R, Kreitz S, Pozharskaya V, Keeperman K, Lai Y, Valcárcel D, Fenaux P, Platzbecker U. Multilineage and Safety Results From the COMMANDS Trial in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s192. DOI: 10.1016/s2152-2650(24)00649-9.
Unveiling the Shadows: Thiamine Deficiency Manifesting as Sudden-Onset Blindness in a Patient With LeukemiaRamachandran S, Stempel J, Podoltsev N, Mahajan A. Unveiling the Shadows: Thiamine Deficiency Manifesting as Sudden-Onset Blindness in a Patient With Leukemia. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s160. DOI: 10.1016/s2152-2650(24)00425-7.
ALL-408 Unveiling the Shadows: Thiamine Deficiency Manifesting As Sudden-Onset Blindness in a Patient With LeukemiaRamachandran S, Stempel J, Podoltsev N, Mahajan A. ALL-408 Unveiling the Shadows: Thiamine Deficiency Manifesting As Sudden-Onset Blindness in a Patient With Leukemia. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s268. DOI: 10.1016/s2152-2650(24)01106-6.
P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.
P-377 Impact of Weekly Versus Twice Weekly Bortezomib on Rates of Peripheral Neuropathy in Combination With Lenalidomide, Dexamethasone and DaratumumabYi I, Gaspar E, Eighmy W, Roeder H, Bar N. P-377 Impact of Weekly Versus Twice Weekly Bortezomib on Rates of Peripheral Neuropathy in Combination With Lenalidomide, Dexamethasone and Daratumumab. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s251. DOI: 10.1016/s2152-2650(24)02279-1.
P-057 Comparative Efficacy of Cilta-Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: A Network Meta-AnalysisMina R, Khan A, McClune B, Bar N, Caers J, Larsen J, Mendes J, Lee S, Benachour N, Chen D, Zhao M, Lonardi C, Slaughter A, Lengil T, Burnett H, Cichewicz A, Neupane B, Filho O, Dytfeld D, Sidana S. P-057 Comparative Efficacy of Cilta-Cel vs Approved Comparator Treatments for Patients With Relapsed/Refractory Multiple Myeloma With 1–3 Prior Lines of Therapy: A Network Meta-Analysis. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s74. DOI: 10.1016/s2152-2650(24)01960-8.
P-008 A Rare and Unexplored Entity of Colitis Post-BCMA Directed CAR T-Cell Therapy; Insights From a Multicenter Case SeriesBar N, Yee A, Dhakal B, Frigault M, Richard S, Cohen A, Susanibar-Adaniya S, Rossi A, Vogl D. P-008 A Rare and Unexplored Entity of Colitis Post-BCMA Directed CAR T-Cell Therapy; Insights From a Multicenter Case Series. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s44-s45. DOI: 10.1016/s2152-2650(24)01911-6.
P-030 Low Infection Rates in Patients (pts) With Relapsed/Refractory Myeloma (RRMM) Treated With Alnuctamab (ALNUC) in a Setting of Infection Reduction Strategies (IRS) and Less Frequent DosingHofmeister C, Bar N, Martin T, Manteca M, Stefanoni P, Yee A, Ribas P, Santoro A, Hansson M, Rodríguez-Otero P, Thompson E, Kiesel B, Cao C, Chen J, Jeyaraju D, Gaudy A, Hsu K, Petrlik E, Godwin C, Costa L. P-030 Low Infection Rates in Patients (pts) With Relapsed/Refractory Myeloma (RRMM) Treated With Alnuctamab (ALNUC) in a Setting of Infection Reduction Strategies (IRS) and Less Frequent Dosing. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s57-s58. DOI: 10.1016/s2152-2650(24)01933-5.
P-096 Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1–3 Lines of TherapyWeisel K, Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Karlin L. P-096 Patient-Reported Outcomes in the Phase 3 CARTITUDE-4 Study of Ciltacabtagene Autoleucel Vs Standard of Care in Patients With Lenalidomide-Refractory Multiple Myeloma After 1–3 Lines of Therapy. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s97-s98. DOI: 10.1016/s2152-2650(24)01999-2.
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.Streiff M, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R, Fertrin K, Fogerty A, Crestani N, Gangaraju R, Rojas-Hernandez C, Goldhaber S, Ibrahim I, Kubal T, Leavitt A, Lim M, Mann J, Mantha S, Morton C, Nester A, O'Brien A, Ortel T, Pine A, Pishko A, Ranade M, Salmasi A, Schaefer J, Williams E, Wool G, Wun T, Montgomery S, Nguyen J, Freedman-Cass D, Sliker B. Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22: 483-506. PMID: 39236759, DOI: 10.6004/jnccn.2024.0046.
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphomaWitzig T, Sokol L, Kim W, de la Cruz Vicente F, García-Sancho A, Advani R, Vidal J, de Oña Navarrete R, Marin-Niebla A, Izquierdo A, Terol M, Domingo-Domenech E, Saunders A, Bendris N, Mackey J, Leoni M, Foss F. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma. Blood Advances 2024, 8: 4581-4592. PMID: 38991123, PMCID: PMC11401221, DOI: 10.1182/bloodadvances.2024012806.
Beyond HMAs: Novel targets and therapeutic approachesGetz T, Bewersdorf J, Kewan T, Stempel J, Bidikian A, Shallis R, Stahl M, Zeidan A. Beyond HMAs: Novel targets and therapeutic approaches. Seminars In Hematology 2024 PMID: 39389839, DOI: 10.1053/j.seminhematol.2024.08.001.
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparisonBar N, Diels J, van Sanden S, Mendes J, Hernando T, Burnett H, Cost P, Schecter J, Lendvai N, Patel N, Ishida T, Er J, Harrison S, Lopez-Muñoz N. Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison. Current Medical Research And Opinion 2024, 40: 1597-1603. PMID: 39129504, DOI: 10.1080/03007995.2024.2391112.
Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysisMuradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.
Impact of Social Needs and Identity Experiences on the Burden of Illness in Patients with Multiple Myeloma: A Mixed-Methods StudyNeparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Impact of Social Needs and Identity Experiences on the Burden of Illness in Patients with Multiple Myeloma: A Mixed-Methods Study. Healthcare 2024, 12: 1660. PMID: 39201218, PMCID: PMC11353550, DOI: 10.3390/healthcare12161660.
Addressing platelet insecurity – A national call to actionGehrie E, Young P, Basavaraju S, Bracey A, P. A, Culler L, Dunbar N, Homer M, Isufi I, Macedo R, Petraszko T, Ramsey G, Tormey C, Kaufman R, Snyder E. Addressing platelet insecurity – A national call to action. Transfusion 2024, 64: 2001-2013. PMID: 39133194, DOI: 10.1111/trf.17987.
The human CD47 checkpoint is targeted by an immunosuppressive Aedes aegypti salivary factor to enhance arboviral skin infectivityMarin-Lopez A, Huck J, Esterly A, Azcutia V, Rosen C, Garcia-Milian R, Sefik E, Vidal-Pedrola G, Raduwan H, Chen T, Arora G, Halene S, Shaw A, Palm N, Flavell R, Parkos C, Thangamani S, Ring A, Fikrig E. The human CD47 checkpoint is targeted by an immunosuppressive Aedes aegypti salivary factor to enhance arboviral skin infectivity. Science Immunology 2024, 9: eadk9872. PMID: 39121194, DOI: 10.1126/sciimmunol.adk9872.
Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and OpportunitiesNeparidze N, Godara A, Lin D, Le H, Fixler K, Shea L, Everson S, Brittle C, Brunisholz K. Patient Perspectives on Social and Identity Factors Affecting Multiple Myeloma Care: Barriers and Opportunities. Healthcare 2024, 12: 1587. PMID: 39201146, PMCID: PMC11354118, DOI: 10.3390/healthcare12161587.
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocolPalmisiano N, Lee J, Claxton D, Paietta E, Alkhateeb H, Park J, Podoltsev N, Atallah E, Schaar D, Dinner S, Webster J, Luger S, Litzow M. A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol. EJHaem 2024, 5: 951-956. PMID: 39415930, PMCID: PMC11474352, DOI: 10.1002/jha2.991.
3007 – T-CELL MEDIATED STEM-LIKE PLASTICITY OF GERMINAL CENTER B CELLSScourzic L, Izzo F, Teater M, Cucereavii L, Polyzos A, Chin C, Mlynarczyk C, Tsialta I, Xia M, Myers R, Mackay S, Hoehn K, Béguelin W, Stadtfeld M, Chen Z, Landau D, Melnick A, Apostolou E. 3007 – T-CELL MEDIATED STEM-LIKE PLASTICITY OF GERMINAL CENTER B CELLS. Experimental Hematology 2024, 137: 104295. DOI: 10.1016/j.exphem.2024.104295.
572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphomaRen J, Liao X, Lewis J, Li D, Chang J, Swallow M, Lee J, Qu R, Carlson K, Foss F, Girardi M. 572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphoma. Journal Of Investigative Dermatology 2024, 144: s100. DOI: 10.1016/j.jid.2024.06.588.
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.Huntington S, Manzoor B, Jawaid D, Puckett J, Emechebe N, Ravelo A, Kamal-Bahl S, Doshi J. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting. Journal Of Managed Care & Specialty Pharmacy 2024, 30: 1106-1116. PMID: 39046941, PMCID: PMC11424914, DOI: 10.18553/jmcp.2024.24049.
Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemiaRojek A, McCormick B, Cwykiel J, Odetola O, Abaza Y, Nai N, Foucar C, Achar R, Shallis R, Bradshaw D, Standridge M, Kota V, Murthy S, Badar T, Patel A. Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia. EJHaem 2024, 5: 728-737. PMID: 39157611, PMCID: PMC11327707, DOI: 10.1002/jha2.981.
Risk prediction for clonal cytopenia: multicenter real-world evidenceXie Z, Komrokji R, Al Ali N, Regelson A, Geyer S, Patel A, Saygin C, Zeidan A, Bewersdorf J, Mendez L, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Chung S, Badar T, Foran J, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg H, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Taylor J, Chandhok N, Soong D, Brunner A, Carraway H, Singh A, Elena C, Ferrari J, Gallì A, Pozzi S, Padron E, Patnaik M, Malcovati L, Savona M, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood 2024, 144: 2033-2044. PMID: 38996210, PMCID: PMC11561536, DOI: 10.1182/blood.2024024756.
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trialDella Porta M, Garcia-Manero G, Santini V, Zeidan A, Komrokji R, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. The Lancet Haematology 2024, 11: e646-e658. PMID: 39038479, DOI: 10.1016/s2352-3026(24)00203-5.
Factor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease.Allen C, Heskel M, Butt A, Tormey C, Pine A, Lee A, Gautam S. Factor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease. Acta Haematologica 2024, 1-5. PMID: 39004080, DOI: 10.1159/000540239.
Longitudinal Curriculum to Address Wellness and Professional Development in a Hematology/Oncology Fellowship ProgramSrikumar T, Stempel J, Goldberg S, Podoltsev N, Braun D, Lee A, Sanft T. Longitudinal Curriculum to Address Wellness and Professional Development in a Hematology/Oncology Fellowship Program. EMJ Oncology 2024, 1: 37-39. DOI: 10.33590/oncolamj/zgwb5064.
Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targetsTaborda C, Zeidan A, Mendez L. Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets. Frontiers In Hematology 2024, 3: 1419323. DOI: 10.3389/frhem.2024.1419323.
Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcomeAlhajahjeh A, Bewersdorf J, Bystrom R, Zeidan A, Shimony S, Stahl M. Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome. Leukemia & Lymphoma 2024, 65: 1541-1551. PMID: 38962996, DOI: 10.1080/10428194.2024.2367040.
Leveraging altered lipid metabolism in treating B cell malignanciesLee J, Mani A, Shin M, Krauss R. Leveraging altered lipid metabolism in treating B cell malignancies. Progress In Lipid Research 2024, 95: 101288. PMID: 38964473, PMCID: PMC11347096, DOI: 10.1016/j.plipres.2024.101288.
Trainees’ perspectives on sickle cell education: a qualitative needs assessmentPrince E, Feder K, Calhoun C, Lee A, Carroll C, Restrepo V, Van Doren L. Trainees’ perspectives on sickle cell education: a qualitative needs assessment. BMC Medical Education 2024, 24: 715. PMID: 38956512, PMCID: PMC11220977, DOI: 10.1186/s12909-024-05696-5.
Clonal Hematopoiesis Is Associated With Cardiomyopathy During Solid Tumor TherapyLeveille E, Cheheyeb R, Matute-Martinez C, Chen N, Jayakrishnan R, Christofides A, Lin D, Im Y, Biancon G, VanOudenhove J, Halene S, Kwan J. Clonal Hematopoiesis Is Associated With Cardiomyopathy During Solid Tumor Therapy. JACC CardioOncology 2024, 6: 605-607. PMID: 39239339, PMCID: PMC11372300, DOI: 10.1016/j.jaccao.2024.05.013.
Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomasDi M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current eraPatel A, Yoon J, Johnston H, Davidson M, Shallis R, Chen E, Burkart M, Oh T, Iyer S, Madarang E, Muthiah C, Gross I, Dean R, Kassner J, Viswabandya A, Madero-Marroquin R, Rampal R, Murthy S, Bradley T, Abaza Y, Garcia J, Gupta V, Pettit K, Cursio J, Odenike O. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Advances 2024, 8: 3468-3477. PMID: 38739724, PMCID: PMC11260843, DOI: 10.1182/bloodadvances.2024012880.

Download Full List